Table 5.
Significantly modified proteins in post treated budesonide versus pre treated budesonide asthmatics
| Swiss Prot Acc. No. | Symbol | Entrez Gene Name | Fold Change | Location | Protein Class |
|---|---|---|---|---|---|
| P01023 | A2M | alpha-2-macroglobulin | -1.27 | Extracellular space | cytokine |
| P04075 | ALDOA | aldolase A, fructose-bisphosphate | -1.22 | Cytoplasm | aldolase |
| P06576 | ATP5B | ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide | -1.76 | Cytoplasm | ATP synthase |
| Q9BPU6 | DPYSL5 | dihydropyrimidinase-like 5 | 2.01 | Cytoplasm | hydrolase |
| P60866 | RPS20 | ribosomal protein S20 | 1.54 | Cytoplasm | ribosomal protein |
| P29508 | SERPINB3 | serpin peptidase inhibitor, clade B (ovalbumin), member 3 | 2.31 | Extracellular space | serine protease inhibitor |
| P08670 | VIM | vimentin | -1.69 | Cytoplasm | structural protein |
© 2000-2011 Ingenuity Systems, Inc. All rights reserved.
All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student's t-test. The fold change for each protein is calculated by dividing the average ratio of the budesonide post treated biopsy with the average ratio of the paired pre budesonide biopsy. The negative fold change indicates down regulation of protein expression after budesonide treatment, while the positive fold change indicates up regulation after budesonide treatment. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.